Company intelligence / Profile preview

Icosagen

Ownership: Private
Employees: ~200
Development stage: Phase 2

Overview

Icosagen develops innovative human biopharmaceutical drug candidates up to Phase I/IIa clinical studies. The company’s main business focuses on providing CRDMO services—antibody discovery, protein production, cell line development, process development, and GMP manufacturing—for global pharmaceutical and biotech companies. It has produced over 2400 different proteins for more than 100 companies worldwide in recent years.[3][5]

Therapeutic areas: Other
Modalities: Monoclonal antibodies (mAbs)Recombinant proteinsAntibody-drug conjugates (ADCs)Cell-based therapeutics[1][5]
Industry: Contract Research Organization

Drug pipeline

1 asset

BioBlock

Pre-clinical

Indications: COVID-19

Partnerships

Salipro Biotech AB – collaboration on membrane protein stabilization technologiespartnerships with >100 pharma/biotech/vaccine developers globally [3][4]

Beyond the preview

Go deeper on Icosagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Icosagen.

Explore the full profile